National Eye Institute to Grant Exclusive Patent License to Opsis Therapeutics for Retinal Pigment Epithelium Cell Transplant Technology

Summary

The National Eye Institute, part of the National Institutes of Health, is set to grant an exclusive patent license to Opsis Therapeutics, a biotech firm based in Madison, Wisconsin, for its innovative cell graft technology aimed at treating retinal degeneration and dysfunction.